LT3609898T - Junginiai, naudingi kaip ret inhibitoriai - Google Patents

Junginiai, naudingi kaip ret inhibitoriai

Info

Publication number
LT3609898T
LT3609898T LTEPPCT/GB2018/050986T LT18050986T LT3609898T LT 3609898 T LT3609898 T LT 3609898T LT 18050986 T LT18050986 T LT 18050986T LT 3609898 T LT3609898 T LT 3609898T
Authority
LT
Lithuania
Prior art keywords
compounds useful
ret inhibitors
ret
inhibitors
compounds
Prior art date
Application number
LTEPPCT/GB2018/050986T
Other languages
English (en)
Inventor
Allan Jordan
Rebecca NEWTON
George Hynd
Jonathan Mark Sutton
Bohdan Waszkowycz
Original Assignee
Cancer Research Technology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Limited filed Critical Cancer Research Technology Limited
Publication of LT3609898T publication Critical patent/LT3609898T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
LTEPPCT/GB2018/050986T 2017-04-13 2018-04-13 Junginiai, naudingi kaip ret inhibitoriai LT3609898T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1705971.8A GB201705971D0 (en) 2017-04-13 2017-04-13 Inhibitor compounds
PCT/GB2018/050986 WO2018189553A1 (en) 2017-04-13 2018-04-13 Compounds useful as ret inhibitors

Publications (1)

Publication Number Publication Date
LT3609898T true LT3609898T (lt) 2022-09-12

Family

ID=58744532

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/GB2018/050986T LT3609898T (lt) 2017-04-13 2018-04-13 Junginiai, naudingi kaip ret inhibitoriai

Country Status (20)

Country Link
US (4) US11352361B2 (lt)
EP (2) EP3609898B1 (lt)
JP (3) JP7277376B2 (lt)
CN (2) CN110506043B (lt)
AU (3) AU2018252251B2 (lt)
BR (1) BR112019021231A2 (lt)
CA (1) CA3059134A1 (lt)
DK (1) DK3609898T3 (lt)
ES (1) ES2925077T3 (lt)
GB (1) GB201705971D0 (lt)
HR (1) HRP20221040T1 (lt)
HU (1) HUE059716T2 (lt)
LT (1) LT3609898T (lt)
PL (1) PL3609898T3 (lt)
PT (1) PT3609898T (lt)
RS (1) RS63514B1 (lt)
RU (1) RU2760669C2 (lt)
SI (1) SI3609898T1 (lt)
SM (1) SMT202200345T1 (lt)
WO (1) WO2018189553A1 (lt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3371171B1 (en) 2015-11-02 2023-10-25 Blueprint Medicines Corporation Inhibitors of ret
GB201705971D0 (en) * 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
WO2019143977A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
WO2019143991A1 (en) * 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
JP6997876B2 (ja) 2018-01-18 2022-02-04 アレイ バイオファーマ インコーポレイテッド Retキナーゼ阻害剤としての置換ピラゾリル[4,3-c]ピリジン化合物
BR112020020273A2 (pt) 2018-04-03 2021-04-06 Blueprint Medicines Corporation Inibidor de ret para uso no tratamento de câncer tendo uma alteração de ret
WO2020033838A2 (en) 2018-08-10 2020-02-13 Blueprint Medicines Corporation Treatment of egfr-mutant cancer
WO2020094084A1 (zh) * 2018-11-07 2020-05-14 南京明德新药研发有限公司 作为ret抑制剂的三并环衍生物
CN111454268B (zh) * 2019-01-18 2023-09-08 明慧医药(上海)有限公司 作为布鲁顿酪氨酸激酶抑制剂的环状分子
WO2020200316A1 (zh) * 2019-04-03 2020-10-08 南京明德新药研发有限公司 作为ret抑制剂的吡唑并吡啶类化合物及其应用
EP4157829A1 (en) 2020-05-29 2023-04-05 Blueprint Medicines Corporation Solid forms of pralsetinib
CN113214294A (zh) * 2020-06-10 2021-08-06 深圳铂立健医药有限公司 三环化合物、药物组合物及其应用
KR20230049668A (ko) * 2020-08-07 2023-04-13 안텐진 디스커버리 리미티드 Atr 억제제 및 이의 용도
EP4194455A4 (en) * 2020-09-29 2024-04-03 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory CRYSTALLINE FORMS OF PYRIDOPYRAZOLE COMPOUNDS AND PRODUCTION PROCESSES THEREOF
US12012398B2 (en) 2021-07-12 2024-06-18 Nido Biosciences, Inc. Bicyclic compounds as androgen receptor modulators
CN117813308A (zh) * 2021-09-14 2024-04-02 中国医药研究开发中心有限公司 含氮稠环类化合物及其制备方法和医药用途
WO2023064843A1 (en) * 2021-10-15 2023-04-20 Stemline Therapeutics, Inc. Inhibitors of mutant ret kinases for use in treating cancer

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0322779A3 (en) 1987-12-29 1991-05-08 Yoshitomi Pharmaceutical Industries, Ltd. Benzolactam compounds and pharmaceutical uses thereof
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
JP4471404B2 (ja) 1996-02-13 2010-06-02 アストラゼネカ ユーケイ リミテッド Vegfインヒビターとしてのキナゾリン誘導体
ATE211134T1 (de) 1996-03-05 2002-01-15 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
DK1553097T3 (da) 1999-02-10 2010-12-13 Astrazeneca Ab Quinazolinderivat som angiogeneseinhibitor og mellemprodukter dertil
NZ522074A (en) 2000-05-31 2004-06-25 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
JP2004502766A (ja) 2000-07-07 2004-01-29 アンギオジェン・ファーマシューティカルズ・リミテッド 血管損傷剤としてのコルヒノール誘導体
CA2410562A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
US9271963B2 (en) 2005-03-03 2016-03-01 Universitat Des Saarlandes Selective inhibitors of human corticosteroid synthases
AU2006316605B2 (en) 2005-11-17 2012-04-26 Osi Pharmaceuticals, Inc. Fused bicyclic mTOR inhibitors
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
WO2007075554A2 (en) * 2005-12-19 2007-07-05 Osi Pharmaceuticals, Inc. Combination of igfr inhibitor and anti-cancer agent
WO2007079164A2 (en) 2005-12-29 2007-07-12 Abbott Laboratories Protein kinase inhibitors
GB0610242D0 (en) 2006-05-23 2006-07-05 Novartis Ag Organic compounds
JP2008063278A (ja) 2006-09-07 2008-03-21 Fujifilm Finechemicals Co Ltd 1−ピリジン−4−イル−インドール類の製造方法
EA018573B1 (ru) 2006-09-22 2013-09-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
EP2178563A2 (en) 2007-07-06 2010-04-28 OSI Pharmaceuticals, Inc. Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mtorc2
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
AU2009204483B2 (en) 2008-01-04 2014-03-13 Intellikine, Llc Certain chemical entities, compositions and methods
RU2513636C2 (ru) * 2008-01-04 2014-04-20 Интелликайн ЭлЭлСи Некоторые химические структуры, композиции и способы
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
MX2011000216A (es) 2008-07-08 2011-03-29 Intellikine Inc Inhibidores de cinasa y metodos para su uso.
WO2010036380A1 (en) * 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
US8476431B2 (en) * 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
US20110269779A1 (en) 2008-11-18 2011-11-03 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
KR101061599B1 (ko) 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
PT2496567T (pt) 2009-11-05 2017-11-15 Rhizen Pharmaceuticals S A Novos moduladores de quinase benzopiran
EP2528919B1 (en) 2010-01-28 2016-11-02 University of Washington Compositions and methods for treating toxoplasmosis. cryptosporidiosis and other apicomplexan protozoan related diseases
US9765037B2 (en) 2010-01-28 2017-09-19 University Of Washington Through Its Center For Commercialization Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
US20110304649A1 (en) * 2010-06-10 2011-12-15 Microsoft Corporation Character selection
US20130296316A1 (en) 2010-07-09 2013-11-07 Michael P. Pollastri Antiparasitic Agents Based On mTOR Inhibitors
JP6130305B2 (ja) 2011-02-23 2017-05-17 インテリカイン, エルエルシー キナーゼ阻害剤の組み合わせおよびそれらの使用
WO2012151562A1 (en) 2011-05-04 2012-11-08 Intellikine, Llc Combination pharmaceutical compositions and uses thereof
HK1198579A1 (en) 2011-08-10 2015-04-30 Novartis Pharma Ag Jak p13k/mtor combination therapy
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
JP6114296B2 (ja) 2011-11-08 2017-04-12 インテリカイン, エルエルシー 複数の医薬品を使用した治療レジメン
WO2013078440A2 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9738610B2 (en) 2012-09-24 2017-08-22 Whitehead Institute For Biomedical Research Indazole derivatives and uses thereof
GB201217285D0 (en) 2012-09-27 2012-11-14 Univ Central Lancashire Indole derivatives
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
WO2014153509A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
JP6397897B2 (ja) * 2013-05-14 2018-09-26 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ ピロロ[2,3−d]ピリミジン誘導体、その製造方法及びキナーゼ阻害剤としてのその使用
US20160272645A1 (en) 2013-10-18 2016-09-22 Medivation Technologies, Inc. Heterocyclic Compounds and Methods of Use
CA2922058A1 (en) 2013-10-18 2015-04-23 Medivation Technologies, Inc. Heterocyclic compounds and methods of use
GB201321146D0 (en) 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
CA2967125C (en) * 2014-11-14 2022-10-25 Nerviano Medical Sciences S.R.L. 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
AU2016211630B2 (en) 2015-01-26 2021-03-25 University Of Washington Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases
KR101766194B1 (ko) * 2015-08-07 2017-08-10 한국과학기술연구원 RET 키나아제 저해제인 신규 3-(이속사졸-3-일)-피라졸로[3,4-d]피리미딘-4-아민 화합물
US10550124B2 (en) 2015-08-13 2020-02-04 San Diego State University Foundation Atropisomerism for increased kinase inhibitor selectivity
TW201722958A (zh) * 2015-09-15 2017-07-01 葛蘭素史克智慧財產(第二)有限公司 化學化合物
WO2017160717A2 (en) 2016-03-15 2017-09-21 Memorial Sloan Kettering Cancer Center Method of treating diseases using kinase modulators
SMT202200348T1 (it) 2016-04-15 2022-11-18 Cancer Research Tech Ltd Composti eterociclici come inibitori della chinasi ret
IL297192A (en) 2016-04-15 2022-12-01 Cancer Research Tech Ltd Heterocyclic compounds as ret kinase inhibitors
GB201705971D0 (en) * 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds

Also Published As

Publication number Publication date
US20250243202A1 (en) 2025-07-31
HUE059716T2 (hu) 2022-12-28
JP2024161432A (ja) 2024-11-19
US20200157107A1 (en) 2020-05-21
EP3609898A1 (en) 2020-02-19
CA3059134A1 (en) 2018-10-18
US11680068B2 (en) 2023-06-20
JP7277376B2 (ja) 2023-05-18
RU2019132155A (ru) 2021-05-13
AU2022202325A1 (en) 2022-04-28
AU2018252251A1 (en) 2019-10-17
US20220348585A1 (en) 2022-11-03
AU2018252251B2 (en) 2022-03-31
EP3609898B1 (en) 2022-06-01
AU2022202325B2 (en) 2024-05-23
AU2024213175A1 (en) 2024-09-12
SMT202200345T1 (it) 2022-09-14
WO2018189553A1 (en) 2018-10-18
CN110506043B (zh) 2022-11-01
US11352361B2 (en) 2022-06-07
CN115785100B (zh) 2025-01-07
CN115785100A (zh) 2023-03-14
EP4105219A1 (en) 2022-12-21
US20240132504A1 (en) 2024-04-25
DK3609898T3 (da) 2022-09-05
RU2019132155A3 (lt) 2021-05-13
ES2925077T3 (es) 2022-10-13
BR112019021231A2 (pt) 2020-04-28
PL3609898T3 (pl) 2022-09-26
JP2023103326A (ja) 2023-07-26
GB201705971D0 (en) 2017-05-31
RS63514B1 (sr) 2022-09-30
RU2760669C2 (ru) 2021-11-29
PT3609898T (pt) 2022-08-25
JP7536949B2 (ja) 2024-08-20
HRP20221040T1 (hr) 2022-11-11
JP2020516636A (ja) 2020-06-11
CN110506043A (zh) 2019-11-26
SI3609898T1 (sl) 2022-11-30

Similar Documents

Publication Publication Date Title
FR24C1016I1 (fr) Inhibiteurs de ret
CY2024003I2 (el) Ενωσεις χρησιμες ως αναστολεις κινασης
LT3609898T (lt) Junginiai, naudingi kaip ret inhibitoriai
IL272249A (en) Organic compounds
LT3371190T (lt) Heterocikliniai junginiai, kaip pi3k-gama inhibitoriai
IL250923A0 (en) Novel compounds as rearranged during transfection (ret) inhibitors
LT3580220T (lt) Aminotriazolopiridinai, kaip kinazės inhibitoriai
DK3728252T3 (da) 4-azaindolforbindelser
LT3442980T (lt) Heterocikliniai junginiai, kaip ret kinazės inhibitoriai
EP3578560A4 (en) QUINAZOLINE COMPOUND
IL256898A (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
LT3377488T (lt) Heterocikliniai junginiai, kaip imunomoduliatoriai
LT3190113T (lt) Pirolopirimidino junginiai, naudotini kaip tlr7 agonistai
EP3609871A4 (en) ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS
DK3582780T3 (da) Aminopyrimidinforbindelser, der er anvendelige som SSAO-inhibitorer
LT3704118T (lt) Aminoimidazopiridazinai, kaip kinazės inhibitoriai
IL255310A0 (en) Thioether compounds as nitrification inhibitors
DK4039675T3 (da) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl forbindelser
DK3544981T3 (da) Benzodiazoliumforbindelser som enac-inhibitorer
DK3717488T3 (da) Substituerede furanopyrimidinforbindelser som pde1-inhibitorer
DK3552017T3 (da) Forbindelser, der er anvendelige som ripk1-inhibitorer
DK3630752T3 (da) Substituerede nitrogenholdige forbindelser
LT3347360T (lt) Junginiai, naudingi ror-gama-t slopinimui
LT3253749T (lt) Junginiai, pasižymintys priešnavikiniu aktyvumu
DK3672941T3 (da) Pyridylpyridonforbindelser